期刊
PHARMACOTHERAPY
卷 32, 期 12, 页码 1095-1111出版社
WILEY
DOI: 10.1002/phar.1147
关键词
tumor angiogenesis; bevacizumab; antiangiogenic therapy; cancer
资金
- University of Georgia (UGA) Research Foundation
- Wilson Pharmacy Foundation of the UGA College of Pharmacy
- Department of Clinical and Administrative Pharmacy
- National Institutes of Health [R01HL103952]
- American Heart Association [0830326N]
The idea of antiangiogenic therapy was the brainchild of Dr. Judah Folkman in the early 1970s. He proposed that by cutting off the blood supply, cancer cells would be deprived of nutrients and, hence, treated. His efforts paid off when bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy in 2004 for the treatment of colon cancer. Since then, an array of antiangiogenic inhibitors, either as monotherapy or in combination with other cytotoxic and chemotherapy drugs, have been developed, used in clinical trials, and approved for the treatment of cancer. Despite this important breakthrough, antiangiogenic therapy for cancer met with a number of hurdles on its way to becoming an option for cancer therapy. In this article, we summarize the most current information on the mechanisms of tumor angiogenesis, proangiogenic and antiangiogenic factors, potential targets and their mechanisms of action, and experimental evidences, as well as the most recent clinical trial data on antiangiogenic agents for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据